# Safety, Pharmacokinetics and Anti-tumor Activity of RP12146, in Patients With Solid Tumors

> **NCT05002868** · PHASE1 · COMPLETED · sponsor: **Rhizen Pharmaceuticals SA** · enrollment: 23 (actual)

## Conditions studied

- Solid Tumor
- Extensive-stage Small-cell Lung Cancer
- Locally Advanced Breast Cancer
- Metastatic Breast Cancer
- Platinum-sensitive Ovarian Cancer
- Platinum-Sensitive Fallopian Tube Carcinoma
- Platinum-Sensitive Peritoneal Cancer

## Interventions

- **DRUG:** RP12146

## Key facts

- **NCT ID:** NCT05002868
- **Lead sponsor:** Rhizen Pharmaceuticals SA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-10-05
- **Primary completion:** 2024-04-25
- **Final completion:** 2024-04-25
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05002868

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05002868, "Safety, Pharmacokinetics and Anti-tumor Activity of RP12146, in Patients With Solid Tumors". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT05002868. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*